IM-1021

Immunome Initiates Phase 1 Trial of ROR1-Targeted ADC for B-Cell Lymphomas and Solid Tumors

2 months ago

• Immunome has dosed the first patient in its Phase 1 trial of IM-1021, a novel ROR1-targeted antibody-drug conjugate designed to treat advanced B-cell lymphomas and solid tumors. • The open-label, multicenter study will evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021, which incorporates Immunome's proprietary TOP1 inhibitor HC74. • This milestone advances Immunome's mission to develop differentiated ADCs for cancer patients with high unmet needs, adding to its growing portfolio of targeted oncology therapeutics.

Immunome Announces Pipeline Advancements, Including Phase 3 Data and Novel ADC Programs

4 months ago

• Immunome anticipates topline data from the Phase 3 RINGSIDE trial of varegacestat for desmoid tumors in the second half of 2025, marking a key milestone. • The FDA has cleared the IND for IM-1021, a ROR1-targeted antibody-drug conjugate (ADC), paving the way for clinical trials. • Immunome is progressing three novel ADC programs—IM-1617, IM-1340, and IM-1335—for solid tumor indications through preclinical development. • An IND submission for IM-3050, a FAP-targeted radioligand therapy, is expected by the end of the first quarter of 2025, expanding Immunome's pipeline.

Immunome Initiates Phase 1 Trial of ROR1-Targeted ADC for B-Cell Lymphomas and Solid Tumors

Immunome Announces Pipeline Advancements, Including Phase 3 Data and Novel ADC Programs

Drug Development Updates